Scleroderma is a rare disease of the connective tissue. It can cause the tissue in skin, joints, and internal organs to thicken and stiffen. There are three major forms of the disease:
- Localized scleroderma (also known as morphea)—usually affects only the skin in isolated parts of the body. This form is less serious.
- Systemic scleroderma—affects widespread areas of skin and/or internal organs, most often the lungs. Certain categories of this form of scleroderma are more serious and can be fatal.
- Overlap syndrome—may involve features of scleroderma and features of other autoimmune syndromes
Overproduction of collagen and other connective tissue proteins is the main feature of scleroderma, but it is not clear what causes this overproduction. Malfunction of the immune system may contribute to excess collagen production. There is also evidence that scleroderma may result from vascular abnormalities.
These factors increase your chance of developing scleroderma. Tell your doctor if you have any of these risk factors:
- Sex: Female
- Age: 30-50 years old
- Occupational exposures (eg, polyvinyl chloride or silica dust)
- Genetic predisposition
Symptoms are usually restricted to the skin. This disorder does not progress to involve internal organs. The skin lesions may completely reverse themselves in a few months or a few years. In some cases, they lead to permanent disfigurement. Symptoms include:
- Hard patches on the skin, most often on the face or trunk (morphea)
- Lines of thickened skin that can extend to underlying muscles and bones (linear scleroderma or linear morphea)
This form of the disease is typically categorized as either limited or diffuse disease. Many cases of limited disease begin gradually with Raynaud's phenomenon]]> . This involves swelling, tingling, numbness, blue and white color, and pain of fingers and toes. It is brought on by cold or emotional distress. The condition can progress over the years to thickened skin.
Raynaud's Phenomenon Symptom
Diffuse scleroderma comes on more suddenly and can progress to involve not only the skin, but the internal organs. Other symptoms of diffuse scleroderma may include:
- Diffuse thickening and hardening of the skin
- Joint and muscular pain, stiffness, and swelling
- Problems with breathing, swallowing, and digesting food due to thickening and hardening of lung, esophagus, bowel tissues
- Inflammation and thickening of large and small blood vessels
Complications of diffuse scleroderma can affect virtually every system of the body. Prominent complications include:
The doctor will ask about your symptoms and medical history, and perform a physical exam. Diagnosis is based on changes in the skin. Other tests may include:
- Blood tests
- Esophagus motility study
- X-ray]]> —a test that uses radiation to take a picture of structures inside the body, especially bones
- ]]>MRI scan]]> —a test that uses magnetic waves to make pictures of structures inside the body
- ]]>CT scan]]> —a type of x-ray that uses a computer to make pictures of structures inside the body
- ]]>Biopsies]]> of skin and other tissues—removing a sample of tissue for testing
There is no treatment to cure scleroderma. Treatments are aimed at relieving symptoms.
Joints and Muscles
- Nonsteroidal anti-inflammatory drugs
Esophagus and Digestive Tract
- Medications to limit acid production in the stomach
- Small, frequent meals
- Sleeping with your head elevated to avoid ]]>acid reflux]]>
Skin and Internal Organs
- Immune suppressants
Kidney Problems and/or High Blood Pressure
- Calcium channel blockers, like ]]>nifedipine]]> —to dilate blood vessels in the extremities
- Proper shelter and clothing to avoid cold
- Not smoking
- Physical therapy and exercise to maintain circulation, joint flexibility, and muscle strength
Scleroderma Research Foundation
Scleroderma Society of Canada
Arthritis Foundation website. Available at: http://www.arthritis.org .
Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol . 2006;54:440-447.
Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J . 2007;29:469-475.
Mayo Foundation for Medical Education and Research website. Available at: http://www.mayo.edu/ .
The Merck Manual of Medical Information . 17th ed. Simon and Schuster, Inc; 2000.
Rodriguez-Reyna TS, Alarcon-Segovia D. Overlap syndromes in the context of shared autoimmunity. Autoimmunity . 2005;38:219-223.
Last reviewed February 2009 by ]]>Jill D. Landis, MD]]>
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2007 EBSCO Publishing All rights reserved.